![]() | |
![]() | |
Clinical data | |
---|---|
Pronunciation | /ˌsaɪproʊˈhɛptədiːn/[1] |
Trade names | Periactin, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682541 |
License data | |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 96 to 99% |
Metabolism | Liver,[3][4] mostly CYP3A4 mediated. |
Elimination half-life | 8.6 hours[2] |
Excretion | Faecal (2–20%; of which, 34% as unchanged drug) and renal (40%; none as unchanged drug)[3][4] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.004.482 |
Chemical and physical data | |
Formula | C21H21N |
Molar mass | 287.406 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Cyproheptadine, sold under the brand name Periactin among others, is a first-generation antihistamine with additional anticholinergic, antiserotonergic, and local anesthetic properties.
It was patented in 1959 and came into medical use in 1961.[5] In 2021, it was the 280th most commonly prescribed medication in the United States, with more than 800,000 prescriptions.[6][7]